{"company":{"id":2132058,"name":"Fore Biotherapeutics","domain":"fore.bio","url":"https://alion.io/company/fore"},"section":"news","answer":"Fore Biotherapeutics: 21 headlines on record, 2 headlines in the last 90 days. Its story counts 4 milestones.","figures":[{"label":"Headlines","value":"21"},{"label":"In 90 days","value":"2"},{"label":"Milestones","value":"4"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":14},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":4}],"news":[{"date":"2026-09-01","kind":"Blog","title":"FORE Biotherapeutics to Participate in Upcoming Investor Conferences","url":"https://fore.bio/fore-biotherapeutics-to-participate-in-upcoming-investor-conferences-5/"},{"date":"2026-09-01","kind":"Blog","title":"FORE Biotherapeutics Announces Positive Outcome from First Planned Interim Efficacy Analysis from FORTE Basket Study Evaluating Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions","url":"https://fore.bio/fore-biotherapeutics-announces-positive-outcome-from-first-planned-interim-efficacy-analysis-from-forte-basket-study-evaluating-plixorafenib-monotherapy-in-advanced-solid-tumors-with-braf-fusions/"},{"date":"2026-07-10","kind":"News","title":"FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance Plixorafenib","source":"Pulse 2.0","url":"https://pulse2.com/fore-biotherapeutics-raises-67-4-million-in-series-d-2-extension-to-advance-plixorafenib/"},{"date":"2026-07-07","kind":"Press release","title":"FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements","url":"https://fore.bio/fore-biotherapeutics-announces-closing-of-upsized-67-4-million-series-d-2-extension-financing-and-highlights-recent-plixorafenib-achievements/"},{"date":"2026-04-02","kind":"Blog","title":"FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib","url":"https://fore.bio/fore-biotherapeutics-receives-breakthrough-therapy-designation-for-plixorafenib/"},{"date":"2025-10-13","kind":"Blog","title":"FORE Biotherapeutics to Host Virtual Key Opinion Leader Roundtable Discussion on Plixorafenib's Potential to Disrupt the BRAF Market to Benefit Patients","url":"https://fore.bio/fore-biotherapeutics-to-host-virtual-key-opinion-leader-roundtable-discussion-on-plixorafenibs-potential-to-disrupt-the-braf-market-to-benefit-patients/"},{"date":"2025-09-24","kind":"Blog","title":"FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors","url":"https://fore.bio/fore-biotherapeutics-announces-positive-outcome-from-a-planned-interim-efficacy-analysis-for-the-forte-basket-study-evaluating-plixorafenib-as-a-monotherapy-for-recurrent-or-progressive-braf-v600-prim/"},{"date":"2025-09-13","kind":"Blog","title":"FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association 2025 Annual Meeting","url":"https://fore.bio/fore_biotherapeutics_presents_plixorafenib_data_ata_2025/"},{"date":"2025-05-22","kind":"News","title":"PRN_FinancialWrapper","source":"PRNewswire","url":"https://markets.financialcontent.com/prnews/article/bizwire-2025-5-22-fore-biotherapeutics-raises-38-million-in-series-d-2-financing-for-the-continued-advancement-of-plixorafenib"},{"date":"2025-05-22","kind":"News","title":"Philadelphia's Fore Biotherapeutics raises $38M in slow year for funding","source":"bizjournals.com","url":"https://bizjournals.com/philadelphia/news/2025/05/22/fore-biotherapeutics-philadelphia-38m-oncology.html"},{"date":"2025-04-23","kind":"Press release","title":"FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency ...","source":"businesswire.com","url":"https://businesswire.com/news/home/20250424007807/en/FORE-Biotherapeutics-Presents-New-Plixorafenib-Results-at-AACR-2025-Demonstrating-Pharmacodynamic-Effect-in-Clinical-Tumor-Biopsies-and-Decreased-V600E-Mutant-Allele-Frequency-in-ctDNA-of-85-of-Patients"},{"date":"2025-03-25","kind":"News","title":"Stock Market","source":"FinancialContent","url":"https://markets.financialcontent.com/stocks/"},{"date":"2024-08-11","kind":"Press release","title":"FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer","source":"businesswire.com","url":"https://businesswire.com/news/home/20240812082028/en/FORE-Biotherapeutics-Names-Michael-Byrnes-as-Chief-Financial-Officer"},{"kind":"News","title":"View the Webcast","source":"edge.media-server.com","url":"https://edge.media-server.com/mmc/p/785xnuuo/"}],"story":[{"title":"Raised a round Series D $67.4M","url":"https://morningstar.com/news/business-wire/20260707991286/fore-biotherapeutics-announces-closing-of-upsized-674-million-series-d-2-extension-financing-and-highlights-recent-plixorafenib-achievements"},{"title":"Raised a round Venture round $38M","url":"https://bizjournals.com/philadelphia/news/2025/05/22/fore-biotherapeutics-philadelphia-38m-oncology.html"},{"title":"New executive FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer · businesswire.com","url":"https://businesswire.com/news/home/20240812082028/en/FORE-Biotherapeutics-Names-Michael-Byrnes-as-Chief-Financial-Officer"},{"title":"Website went live first capture in the Wayback Machine","url":"https://web.archive.org/web/20210222152634/fore.bio"}],"as_of":"2026-11-17","cite":"Fore Biotherapeutics, News. Alion, Nov 17, 2026. https://alion.io/company/fore/news","html_url":"https://alion.io/company/fore/news","json_url":"https://alion.io/company/fore/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T22:45:58Z"}}